Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
BLBellerophon Therapeutics, Inc. logo

Bellerophon Therapeutics, Inc. (BLPH)

NASDAQ Capital Market · Currency in USD
$0.01 ▼ -0.01 (-36.84%)
At close: Dec 18, 12:51 PM ET. Market closed.

Summary

Previous Close
$0.02
Open
$0.01
Day's Range
$0.01 – $0.01
52 Week Range
$0.01 – $0.10
Volume
1,565
Avg. Volume
13,286
Market Cap
$146.79K
Beta (5Y Monthly)
0.70
PE Ratio (TTM)
--
EPS (TTM)
-$2.08
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
Dec 19, 2024
1y Target Est
--

Profile: Bellerophon Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
18
CEO
Craig R. Jalbert CIRA

Bellerophon Therapeutics, Inc. is a U.S.-based clinical-stage pharmaceutical company primarily focused on developing novel therapies for various cardiopulmonary conditions. Its flagship product is INOpulse, a proprietary platform designed to deliver pulsatile nitric oxide, specifically targeting pulmonary hypertension (PH). The company is actively advancing the development of INOpulse across multiple indications: Currently, INOpulse is undergoing a Phase 3 clinical trial for pulmonary hypertension linked to fibrotic interstitial lung disease.

Earnings

DateEst.Actual
Nov 14, 2023-$0.44-$0.16Beat
Aug 14, 2023-$0.42-$0.42Beat
May 15, 2023-$0.48$0.27Beat
Mar 31, 2023-$0.48-$0.53Miss
Nov 14, 2022-$0.59-$0.53Beat
Aug 15, 2022-$0.61-$0.43Beat

Analyst view

Rating: Buy
Buy 88% · Hold 13% · Sell 0%

Get free alerts on BLPH and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.